Ningxia Kangya Pharmaceutical's Calcium Dobesilate Capsules First to Pass National Generic Drug Consistency Evaluation

On November 18, Ningxia Kangya Pharmaceutical Co., Ltd. announced that it had recently received the "Drug Supplementary Application Approval" (Approval No.: 2019B04194) approved and issued by the National Medical Products Administration regarding Calcium Dobesilate Capsules. This drug is the first to pass the consistency evaluation of quality and efficacy for generic drugs.

Calcium Dobesilate Capsules are primarily used for the prevention and treatment of diabetic retinopathy. They are internationally recognized as safe and effective medications for preventing and treating microcirculatory disorders, and are the drug of choice for the prevention and treatment of diabetic retinopathy.

Calcium Dobesilate Capsules have been included in the National Class B Medical Insurance Drug List. Currently, apart from Kangya Pharmaceutical, the major domestic manufacturers of Calcium Dobesilate Capsules include Shanghai Zhaohui Pharmaceutical, Guizhou Tian’an Pharmaceutical, Xi’an Lijun Pharmaceutical, Shanghai Haihong Industrial (Group) Chaohu Jinchen Pharmaceutical, and Beijing Jingfeng Pharmaceutical.

Ningxia Kangya Pharmaceutical Co., Ltd. stated that the company is the first pharmaceutical manufacturer in Northwest China to pass the consistency evaluation. Its Calcium Dobesilate Capsules were the first to receive approval, which helps enhance the market competitiveness of this drug and accumulates valuable experience for the company’s subsequent generic drug consistency evaluation efforts.